Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Bortezomib represents the first proteasome inhibitor (PI) with demonstrated antitumor activity in the clinical setting, particularly for treatment of hematological malignancies. At the preclinical level, its action is shown to be mediated by induction of growth arrest and apoptosis in many tumor types, including androgen-dependent (AD) and androgen-independent (AI) prostate cancer (PCa) cells. Hypoxia-inducible factor-1α (HIF-1α), which is directly involved in tumor growth, is one of the most studied and promising molecular targets for anti-cancer therapy and is often overexpressed in PCa. Bortezomib has been reported to impair tumor growth by also inhibiting HIF-1α. In this study, we investigated the effect of bortezomib on the expression, activity and localization of HIF-1α in LNCaP (AD) and PC3 (AI) PCa cells. First, we show that hypoxic upregulation of HIF-1α protein levels and activity involves both the PI3K/Akt/mTOR and p44/42 MAPK pathways. Second, bortezomib inhibits expression of HIF-1α protein under both normoxic and hypoxic conditions, represses HIF-1 transcriptional activity and attenuates the release of vascular endothelial growth factor. These effects correlate with the ability of bortezomib to cause dephosphorylation of phospho-Akt, phospho-p70S6K, and phospho-S6RP, thus inactivating a pathway known to be required for HIF-1α protein expression at the translational level. Furthermore, bortezomib also abrogates p44/42 MAPK phosphorylation, which results to reduce…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PT2977 (also known as MK-6482, Belzutifan), a PT2385 derivative with improved pharmacokinetic profile and potency, demonstrated promising single-agent activity in heavily pre-treated patients with advanced ccRCC, and in VHL-associated non-metastatic ccRCC, and was recently approved by the FDA for the treatment of cancers associated with VHL disease [23,24] [25].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [24]
In the citing paper
“Bortezomib, a proteasome inhibitor, inhibits the recruitment of p300 and blocks the PI3K/Akt/TOR pathway, which inhibits HIF-1α synthesis and activation at multiple levels, but does not affect HIF-2α [24,90].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [24]
In the citing paper
“More recently, the ability of bortezomib to downregulate the PI3K/AKT/mTOR pathway which is upstream of the HIF-1 pathway was demonstrated in prostate cancer cells79.”
From HIF-1α pathway: role, regulation and intervention for cancer therapy (2015) · cites this paper as [79]
In the citing paper
“bortezomib treatment resulted in impaired phosphorylation of p44/42 MAPK (ERK1/2), which manifested as a substantial decrease in nuclear HIF-1α coupled with redistribution of the protein toward the cytoplasmic fraction under hypoxic conditions [339].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [339]
In the citing paper
“This demonstrates that MAPK signaling regulates HIF-1α activity primarily through control of its subcellular localization, rather than through modulation of protein abundance [339].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [339]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1999) · PubMed · Cited by 2,204
Transformation of Mammalian Cells by Constitutively Active MAP Kinase Kinase
Mansour, S. J., Matten, W. T., Hermann, A. S., Candia, J. M., Rong, S., Fukasawa, K., Vande Woude, G. F., & Ahn, N. G. (1994) · Science · doi:10.1126/science.8052857 · Cited by 1,353 · cited 1×
“On the other hand, enhanced MAPK signaling is a common event in neoplasia as constitutively active MAPK signaling transforms benign mammalian cells to malignant [7].”
Richard, D. E., Berra, E., Gothié, E., Roux, D., & Pouysségur, J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.46.32631 · Cited by 790
Development of the Proteasome Inhibitor Velcade™ (Bortezomib)
Adams, J., & Kauffman, M. (2004) · Cancer Investigation · doi:10.1081/cnv-120030218 · Cited by 654 · cited 1×
“Bortezomib (PS-341, Velcade®) is a specific and reversible boronate inhibitor of the chymotryptic activity of the 20S proteasome currently approved for the treatment of multiple myeloma and mantle cell lymphoma [1].”
Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis
(2009) · Advances in Cancer Research · doi:10.1016/s0065-230x(09)02002-8 · Cited by 620 · cited 2×
“Indeed, Akt-dependent activation of p70S6K and its downstream target S6RP, known to lead to stimulation of HIF-1α expression [6], were markedly reduced after treatment with bortezomib, which in parallel decreased HIF-1α protein level in both PCa cell lines.”
Regulation of cancer cell metabolism by hypoxia-inducible factor 1
Semenza, G. L. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.11.009 · Cited by 469 · cited 13×
“Baseline VEGF secretion levels of both cell lines in normoxia were also decreased after treatment with bortezomib (Fig.”
InfluentialKinkade, C. W., Castillo-Martin, M., Puzio-Kuter, A., Yan, J., Foster, T. H., Gao, H., Sun, Y., Ouyang, X., Gerald, W. L., Cordon-Cardo, C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34764 · Cited by 391 · cited 1×
“Targeting both Akt/mTOR and MAPK signaling pathways may be an effective treatment for patients with advanced prostate cancer, particularly those with hormone-refractory disease [35].”
MAPK Signaling Up-regulates the Activity of Hypoxia-inducible Factors by Its Effects on p300
Sang, N., Stiehl, D. P., Bohensky, J., Leshchinsky, I., Srinivas, V., & Caro, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209702200 · Cited by 370 · cited 1×
“p44/42 (also known as ERK1/2) refers to two serine/threonine kinases of the MAPK signaling pathway that have been implicated in HIF-1 activation by promoting the formation and modulating the transactivation activity of the HIF-p300/CBP complex [8].”
Roccaro, A. M., Hideshima, T., Raje, N., Kumar, S., Ishitsuka, K., Yasui, H., Shiraishi, N., Ribatti, D., Nico, B., Vacca, A., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1195 · Cited by 284 · cited 1×
“Bortezomib indirectly inhibits angiogenesis in multiple myeloma and endothelial cells by decreasing vascular endothelial growth factor (VEGF) levels [3], and these effects involve the repression of HIF-1[4].”
Mylonis, I., Chachami, G., Samiotaki, M., Panayotou, G., Paraskeva, E., Kalousi, A., Georgatsou, E., Bonanou, S., & Simos, G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605058200 · Cited by 266 · cited 4×
“To examine the transcriptional activity of HIF-1, LNCaP and PC3 cells were cotransfected with the firefly luciferase reporter plasmid pGL3–5HRE-VEGF and the Renilla luciferase expressing plasmid PCIRenilla, under the control of an autologous promoter (pGL3) as previously described [10, 11].”
InfluentialSelf-citation
Cited by
HIF-1α pathway: role, regulation and intervention for cancer therapy
Masoud, G. N., & Li, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.05.007 · Cited by 1,871
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
Semenza, G. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.005 · Cited by 1,514
“In prostate cancer cells, bortezomib blocks HIF-1α protein expression by inhibiting phosphatidylinositol-3-kinase/AKT/mTOR and ERK signaling [70].”
BackgroundCancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target
Infantino, V., Santarsiero, A., Convertini, P., Todisco, S., & Iacobazzi, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115703 · Cited by 499
“Similarly, bortezomib, a proteasome inhibitor, acts as a repressor of HIF-1α transcription, translation, and blocks the recruitment of the coactivator p300 [152,153].”
BackgroundMimeault, M., & Batra, S. K. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12004 · Cited by 330
Up-down regulation of HIF-1α in cancer progression
Rashid, M., Zadeh, L. R., Baradaran, B., Molavi, O., Ghesmati, Z., Sabzichi, M., & Ramezani, F. (2021) · Gene · doi:10.1016/j.gene.2021.145796 · Cited by 283
Metadata
- Authors
- Befani, C. D., Vlachostergios, P. J., Hatzidaki, E., Patrikidou, A., Bonanou, S., Simos, G., Papandreou, C. N., & Liakos, P.
- Affiliations
- University of Thessaly (GR)
- Corresponding author
- Papandreou, Christos N.
- Liakos, Panagiotis
- Venue
- Journal of Molecular Medicine
- Published
- 2011-09-10
- Volume
- 90
- Issue
- 1
- Pages
- 45-54
- ISSN
- 0946-2716 (ISSN-L)
- 1432-1440
- OpenAlex
- W2036941876
- Cited by
- 135
- References
- 35
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 4 · 2023: 11 · 2022: 11 · 2021: 18 · 2020: 6 · 2019: 11 · 2018: 2 · 2017: 8 · 2016: 12 · 2015: 16 · 2014: 7 · 2013: 14 · 2012: 6
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Molecular Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Thessaly Institutional Repository (University of Thessaly) (submittedVersion)
- Funders
- University of Thessaly
- Janssen Pharmaceuticals
- Cilag
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- bortezomib, HIF-1α, prostate cancer, PI3K/AKT/mTOR pathway, MAPK signaling, proteasome inhibitors, hypoxia, nuclear translocation, vascular endothelial growth factor, Akt dephosphorylation, p70S6K, castration-resistant prostate cancer, androgen-dependent prostate cancer, LNCaP cells, PC-3 cells
- MeSH terms
- Bortezomib, Phosphoinositide-3 Kinase Inhibitors, Hypoxia, Antineoplastic Agents, Boronic Acids, Cell Nucleus, Humans, Male, Prostatic Neoplasms, Pyrazines, Transcription, Genetic, Signal Transduction, Gene Expression Regulation, Neoplastic, Mitogen-Activated Protein Kinases, Cell Line, Tumor, Proto-Oncogene Proteins c-akt, Hypoxia-Inducible Factor 1, alpha Subunit, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. https://app.cochat.ai/papers/10.1007/s00109-011-0805-8
- The paper
- Befani, C. D., Vlachostergios, P. J., Hatzidaki, E., Patrikidou, A., Bonanou, S., Simos, G., Papandreou, C. N., & Liakos, P. (2012). Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. Journal of Molecular Medicine. https://doi.org/10.1007/s00109-011-0805-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.